2009 Midyear Clinical Meeting
Click here to go to the previous page
Contemporary Considerations in the Evaluation of Antithrombotic Use in Percutaneous Coronary Intervention
Track:
Educational Sessions (CE)
Program Code: 253-L01
Date: Wednesday, December 9, 2009
Time: 8:00 AM to 9:30 AM EST
Location:
2405 - Veronese
MEETING PLANNING ASSOCIATE:
Click the plus sign to see more detailed information about each speaker.
Alisa Goetz,
PharmD, Director, Clinical Data and Analytics,
Cardinal Health
Alisa Goetz, Pharm.D is Director of Clinical Data and Analytics for the Pharmacy Services business of Cardinal Health. She is responsible for the use of drug informatics systems to support both clinical and operational initiatives within the organization.
During her 20 year tenure with Cardinal Health, Alisa has held various product development and clinical positions. Prior to her current role, she served as one of the core team members of the Integrated Medication Solutions (IMS) Development Team responsible for new product design and management of Cardinal's Medication Cost Control Solution. Prior to her role with IMS, Alisa was the Senior Director of Pharmaceutical and Clinical Information Services and was responsible for the creation of the Houston-based Data and Custom Studies Research businesses. In this role, she was involved in all aspects of clinical outcomes research including project conceptualization, design, sales, management, data analysis, presentation and publication. Prior to her role in PCIS, Alisa was the Senior Director of Clinical Affairs-Contract Development and Product Evaluation for the Pharmacy Management division. In this role she served as the corporate liaison between Clinical Affairs and Cardinals GPO overseeing the Corporate Formulary product selection for over 250 Pharmacy Management hospital accounts and participating in clinical contract negotiations. Alisa has 8 years experience as a field-based clinical pharmacist where she served as Clinical Director and Assistant Director of Pharmacy.
|
PRESENTER(S):
Click the plus sign to see more detailed information about each speaker.
Alisa Goetz,
PharmD, Director, Clinical Data and Analytics,
Cardinal Health
Alisa Goetz, Pharm.D is Director of Clinical Data and Analytics for the Pharmacy Services business of Cardinal Health. She is responsible for the use of drug informatics systems to support both clinical and operational initiatives within the organization.
During her 20 year tenure with Cardinal Health, Alisa has held various product development and clinical positions. Prior to her current role, she served as one of the core team members of the Integrated Medication Solutions (IMS) Development Team responsible for new product design and management of Cardinal's Medication Cost Control Solution. Prior to her role with IMS, Alisa was the Senior Director of Pharmaceutical and Clinical Information Services and was responsible for the creation of the Houston-based Data and Custom Studies Research businesses. In this role, she was involved in all aspects of clinical outcomes research including project conceptualization, design, sales, management, data analysis, presentation and publication. Prior to her role in PCIS, Alisa was the Senior Director of Clinical Affairs-Contract Development and Product Evaluation for the Pharmacy Management division. In this role she served as the corporate liaison between Clinical Affairs and Cardinals GPO overseeing the Corporate Formulary product selection for over 250 Pharmacy Management hospital accounts and participating in clinical contract negotiations. Alisa has 8 years experience as a field-based clinical pharmacist where she served as Clinical Director and Assistant Director of Pharmacy.
|
Carl Peterson,
PharmD, Clinical Director, Cardiovascular Diseases,
Cardinal Health
Carl Peterson, Pharm.D., is Clinical Director, Cardiovascular Diseases for the Clinical Affairs team of Cardinal Health Pharmacy Services. He is responsible for supporting Cardinal businesses as well as health care providers at Cardinal client hospitals in the area of cardiovascular therapeutics with special emphasis on pharmacotherapy in coronary and peripheral arterial disease as well as prevention and treatment of thromboembolic diseases.
Before joining Cardinal Health in 1995 Carl was a member of the University of Illinois College of Pharmacy faculty as Clinical Assistant Professor of Pharmacy Practice and Clinical Pharmacist, Peripheral Vascular Surgery, at University of Illinois Hospital. He later served as Assistant Director for Clinical Pharmacy Services and Director, Lutheran General Anticoagulation Center, at Advocate Lutheran General Hospital in Park Ridge, Illinois.
Carl earned his Bachelor of Science in Pharmacy from University of Illinois and his Doctor of Pharmacy from Philadelphia College of Pharmacy and Science. He completed his clinical residency at University of Illinois.
|
Description
ACPE Activity #204-000-09-253-L01P
1.5 Contact Hours / Knowledge-based
Educational Content: Level 2
Moderator: Alisa E. Goetz, PharmD, Director, Clinical Data and Analytics, Cardinal Health, Houston, TX
8:00 a.m. – 8:05 a.m.
Announcements
8:05 a.m. – 8:15 a.m.
Review of Current Guidelines for Antithrombotic Use in PCI
Carl Peterson, PharmD, Clinical Director, Cardiovascular Diseases, Cardinal Health, Houston, TX
8:15 a.m. – 8:35 a.m.
Review of Recent PCI Clinical Trial Results
Carl Peterson
8:35 a.m. – 8:40 a.m.
Case Study Presentation
Carl Peterson
8:40 a.m. – 9:00 a.m.
Evaluation of Real World PCI Data
Alisa E. Goetz
9:00 a.m. – 9:05 a.m.
Audience Polling: Practice Patterns of Participants and Case Study Evaluation
Alisa E. Goetz
9:05 a.m. – 9:20 a.m.
Impact Analysis Comparing Real World Data to Clinical Trial Data Including Economic Implications
Carl Peterson
9:20 a.m. – 9:30 a.m.
Conclusions, Questions, Answers, and Discussion
Learning Objectives:
LEARNER OUTCOMES:
- Describe and interpret the results of recent clinical trial data including the REPLACE, ISAR-REACT, and ACUITY trials.
- Describe PCI drug utilization data for over 50 acute care hospitals with focus on the use of bivalrudin and glycoprotein IIb/IIIa receptor inhibiters (GPI).
- Identify variances between clinical practices, guideline recommendations, and results from recent clinical trials.
- Summarize current clinical guidelines for the use of antithrombotics in percutaneous coronary intervention (PCI).
- Summarize the clinical and economic implications of variance in antithrombotic drug use during PCI in clinical practice, guideline recommendations, and recent clinical trial results.